Last reviewed · How we verify

NCT03817242: PTA

Half-thickness Tragal Cartilage Graft vs Temporalis Fascia Graft Tympanoplasty Type I

Completed NA Last updated 25 January 2019
What this trial tests

NA trial testing Tympanoplasty using tragal cartilage graft in Hearing Loss,Conductive in 40 participants. Completed in 31 December 2017.

Timeline
1 January 2017
Primary endpoint
31 December 2017
31 December 2017

Quick facts

Lead sponsorLady Reading Hospital, Pakistan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 January 2017
Primary completion31 December 2017
Estimated completion31 December 2017
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Lady Reading Hospital, Pakistan

Who can join

Adults 16 to 60, any sex, with Hearing Loss,Conductive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The rationale of this study is to find out the surgical outcome and success rates of tragal cartilage and temporalis fascia, subsequently to develop guide line in light of the results of this study for our department as our institute is going to follow one patient in one bed policy in future. The purpose of this study is to compare the graft success rate of cartilage versus temporalis fascia in tympanoplasty type I in our institute, as no such study has been conducted in our province before.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Lady Reading Hospital, Pakistan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing